Advanced therapy for inflammatory bowel disease: A guide for the primary care physician

Journal of the American Board of Family Medicine

Volumn 27, Issue 3, 2014, Pages 411-420

  Thomas, Arul ^a   Lodhia, Nilesh ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Biologic therapy; Immunomodulatory therapy; Inflammatory bowel diseases

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; BIOLOGICAL FACTOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE PANCREATITIS; ARTHRALGIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; FAMILY PLANNING; FOLLOW UP; GASTROENTEROLOGIST; GENERAL PRACTITIONER; HAIR LOSS; HUMAN; HYPOTENSION; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER FIBROSIS; MAINTENANCE THERAPY; NAUSEA; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STOMATITIS; THORAX PAIN; INFLAMMATORY BOWEL DISEASES; PRIMARY HEALTH CARE;

BIOLOGICAL FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PRIMARY HEALTH CARE;

EID: 84900541030     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2014.03.130224     Document Type: Review

References (65)

1. Modigliani R, Mary JY, Simon JF, et al. Clinical, biologic, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1998;98:811-8.
2. Spurio FF, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis 2012;21:67-73.
3. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
4. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31.
5. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
6. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effective analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005;100:2239-47.
7. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006;24:767-81.
8. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochran Database Syst Rev 2000;(2):CD000067.
9. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's Disease. Cochrane Database Syst Rev 2013;(4):CD000545.
10. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
11. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004;33:209-34.
12. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
13. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
14. Kotylar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T cell lymphoma. Clin Gastroenterol Hepatol 2011;9:36-41.e31.
15. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8.
16. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
17. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
18. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
19. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9.
20. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9.
21. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of longterm methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150-6.
22. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
23. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007;132:1672-83.
24. Sands BE, Francis G, Belcher G, et al. The Touch program and risk management plan for the administration of natalizumab: lessons and updated safety results from the use of natalizumab in patients with relapsing multiple sclerosis and implications for potential use in Crohn's disease. Gastroenterology 2008;134:A206.
25. Dassopoulos T, Sninsky CA. Optimizing immunomodulators and anti-TNF agents in the therapy of Crohn disease. Gastroenterol Clin North Am 2012;41:393-409.
26. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med 2004;350:876-85.
27. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's Disease. Gut 2009;58:940-8.
28. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-TNF therapy guided by MRI for Crohn's perineal fistulas. Am J Gastroenterol 2009;104:2973-86.
29. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
30. Hanauer SB, Rutgeerts PJ, D'Haens G, et al. Delayed hypersensitivity to infliximab (Remicade) reinfusion after 2-4 year interval without treatment. Gastroenterology 1999;116:A731.
31. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
32. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
33. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
34. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108:99-105.
35. Nozaki K, Silver RM, Stickle DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 2011;342:352-5.
36. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006;24:715-29.
37. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):V1-16.
38. Wallace TM, Veldhuyzen van Santen SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can J Gastroenterol 2001;15:21-8.
39. Azasan package insert. Raleigh, NC: Salix Pharmaceuticals, Inc; 2011.
40. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-6.
41. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF alpha drugs during pregnancy with inflammatory bowel disease. Am J Gastroenterol 2013;108:433-40.
42. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17.
43. Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SF. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998;93:2426-30.
44. Mahadevan U. Pregnancy and inflammatory bowel disease. Gastroenterol Clin North Am 2009;38:629-49.
45. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008;28: 1209-13.
46. Moretti ME, Verjee Z, Ito S, Koren G. Breastfeeding during maternal use of azathioprine. Ann Pharmacother 2006;40:2269-72.
47. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006;62:453-6.
48. Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe? BJOG 2007;114:498-501.
49. Mahadevan U, Kane S. American Gastroenterological Association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006;131:283-311.
50. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
51. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003;21:3365-9.
52. Banaszkiewicz A, Radzikowski A. More on vaccinations in IBD patients. Am J Gastroenterol 2011;106:545-6.
53. Mahadevan U, Church J, Vasiliauskas E, Sandborn W, Dubinsky M. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008;134:A69.
54. Mahadevan U, Abreu M. Certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology 2009;136:A960.
55. Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Dig Liver Dis 2013; 45:787-94.
56. Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001;121: 1048-53.
57. Teruel C, López-San Román A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010;105:2003-8.
58. Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:395-9.
59. El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. Arch Androl 1979;3:177-9.
60. Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981;22:445-51.
61. Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin North Am 2012;41:325-37.
62. Agrawal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012;30:1413-24.
63. Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1158-60.
64. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631-6.
65. Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics 2011;29:387-401.